text:
Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer
The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2013 by Yonsei University.
Recruitment status was: Recruiting
Recruitment status was: Recruiting
Yonsei University
Information provided by (Responsible Party):
Yonsei University
ClinicalTrials.gov Identifier:
First received: January 24, 2011
Last updated: June 1, 2013
Last verified: June 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Docetaxel was the first drug that showed survival benefits when added to the CF regimen, but it was very toxic. Docetaxel is also has a synergistic anti-cancer effect with S-1, in phase I/II studies. The use of a docetaxel plus S-1 combination as first-line chemotherapy for advanced gastric cancer achieved response rates of 46~56% and a median survival time of 14.0~14.3 months.
Based upon this background, the aim of this study is to detect a significant increase in 3 year DFS of disease for the test group (DS) relative to the Control group (SP).
|Gastric Adenocarcinoma
|Drug: DS Drug: SP
|Phase 3
|Study Type:
|Study Design:
|Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:
|A Randomized, Multicenter, Open-label, Phase III Trial of Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected (D2) Gastric Cancer of Stage IIIB/IV (M0)
Resource links provided by NLM:
MedlinePlus related topics: Stomach Cancer
Drug Information available for: Cisplatin DocetaxelU.S. FDA Resources
Further study details as provided by Yonsei University:
Primary Outcome Measures:
- 3-year disease free survival(DFS) [ Time Frame: 3 years ]Tumor assessments with chest X-rays and CT or MRI scan will be done at 6 months after randomization (after the end of the treatment period), then every 3 months for the first 2 years after randomization and then every 6 months for coming 3 years then one year basis until completion of the study.
|Estimated Enrollment:
|Study Start Date:
|March 2010
|Estimated Study Completion Date:
|March 2016
|Estimated Primary Completion Date:
|March 2016 (Final data collection date for primary outcome measure)
|Assigned Interventions
Experimental: DS(Docetaxel with S-1)
Docetaxel with S-1
Drug: DS
Docetaxel with S-1. S-1: Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.
Other Names:
Active Comparator: SP(S-1 with cisplatin)
S-1 with cisplatin
Drug: SP
S-1 with cisplatin. S-1 : Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.
Other Names:
|Ages Eligible for Study:
|20 Years and older (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion Criteria:
- Histologically proven, Stage IIIb/ IIIc curatively resected gastric carcinoma
- ECOG performance status 0-1
- Curatively resected advanced gastric cancer patients of stage IIIb/IIIc
- D2 lymph node dissection with R0 surgery
- Signed informed consent
Exclusion Criteria:
- Subjects with documented distant metastasis.
- Malabsorption syndrome or disease significantly affecting gastrointestinal function
- Patients with other uncontrolled systemic illness, e.g. infection, poorly controlled HTN
- History of other malignancy. Subjects who have been disease-free for 5 years or subjects with successfully treated in situ carcinoma are eligible.
- Subjects with preoperative/adjuvant other cancer treatment, such as chemotherapy, immunotherapy and radiotherapy
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01283217
Please refer to this study by its ClinicalTrials.gov identifier: NCT01283217
|Korea, Republic of
|Severance Hospital
|Seoul, Korea, Republic of, 120-752
|Contact: Sun-Young Rha, MD, Ph.D 82-2-2228-8050 email@example.com
Sponsors and Collaborators
Yonsei University
More Information
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on August 18, 2017
|Responsible Party:
|Yonsei University
|ClinicalTrials.gov Identifier:
|NCT01283217 History of Changes
|Other Study ID Numbers:
|Study First Received:
|January 24, 2011
|Last Updated:
|June 1, 2013
Additional relevant MeSH terms:
Stomach Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
ClinicalTrials.gov processed this record on August 18, 2017


text:
found a new home!
Plenty of my friends are looking
for one too. Find a pet to adopt.
I am already spayed, up to date with shots, and not good with cats.
Gypsy, a Scottsdale Domestic Longhair cat was adopted! Here's how you can benefit by looking at adoption as an option to buying a Domestic Longhair for sale in Scottsdale, or seeking a Domestic Longhair cat from a breeder in Scottsdale.

subset: commoncrawl


text:
Simon Open Door
Tuesday, 8 April 2008
The RIAI (Royal Institute of Architects in Ireland) & the Simon Communities of Ireland have once again joined forces for a special fundraising initiative called "Simon Open Door" - whereby participating RIAI Architects around Ireland will open their offices on Saturday 12th April 2008, to give members of the public an hour's consultation with an architect in return for a donation to Simon of €75. All of this money goes to the Simon Community.
This is the fourth year of the Open Door initiative and since 2005 they have raised nearly €90,000. Over €38,000 was raised last year alone with 545 people visiting RIAI architects. The RIAI this year hope to raise at least €50,000 for Simon whilst providing expert professional advice to members of the public who are planning a building project.
The deadline for appointments is tomorrow, April 9th and the consultations will take place this coming Saturday, April 12th.
Kathryn Meghen - Architect registered with RIAI
Patrick Burke - CEO Simon Communities of Ireland
How did this project initially come about?
As Simon doesn't receive 100% funding from the government, they often rely on the generosity of the public and from corporations. Companies can provide considerable funding, but often require something in return. As there is a clear connection between architects and the notion of designing houses, and homeless people, this was seen as a great opportunity by both sides, to come together and work in partnership.
How much are you hoping to raise this year?
To date as many as 600 bookings have been made, so the campaign are hoping to raise roughly 50-60,000. This would be a significant improvement on previous years.
What does the money go towards and how much of a difference does it make?
Where money is donated locally, it stays locally. Funding goes towards outreach services, soup runs, emergency accommodation, transitional homes- a full spectrum of services for homeless people. There are also services provided for the service users who are suffering with mental illnesses. Essentially Simon tries to design its services around its users.
The difference the money makes is black and white. It's the difference between people sleeping on the streets and having a roof over their heads, be it for one night or many. Services in Cork are at present turning 20 people away each week- potentially the Open Door campaign could end this.
How many people are homeless in Ireland at present?
Determining the number of people who are homeless at any given point is logistically a difficult task. Official government figures are based on the last Housing Needs Assessment, undertaken in 2005. This shows that 2,399 households were categorised as homeless in 2005, with 1,725 households living in unfit accommodation, 4,112 in overcrowded accommodation and 3,375 involuntarily sharing. This only reflects a snapshot of the situation on one night and does not reflect the experiences of many more families that are impacted by homelessness throughout the year. The definition of homelessness used is also subject to interpretation by the local authorities that undertake this assessment, and different authorities apply it in different ways. As we worked with 3,346 people experiencing homelessness or at risk of homelessness in 2006, we believe that the figure may be more significant than that officially recorded.
What the Simon community does:
The Simon Communities of Ireland is the National Affiliation of Simon Communities in Cork, Dublin, Dundalk, Galway, Midlands & South East. In 2006, Communities in the North West and Mid West were added, meaning, Simon now covers every local authority area in the State.
The Simon Communities of Ireland have a vision of society where no one is homeless i.e., no one is without a home for longer than is an emergency and everyone will receive support that will allow them to progress out of homelessness. Throughout the country they deliver a range of activities based on a continuum of care approach including outreach, day centres, emergency shelter, addiction support, transitional accommodation, long term supported housing, resettlement, prevention services and training and employment services.
How has this project caught on?
This is the fourth year of the campaign- initially 60/70 architects got involved but this year there are as more than 170 architects nationwide participating in every county - except Longford. This may change as architects are signing up all the time. As well as supporting a great cause, this project gives architects the chance to meet members of their own communities.
What can members of the public gain from this experience?
Although they won't walk away from their hour-long consultation with blueprints for new designs, they will get a new perspective, maybe some new ideas and suggestions as to how they could improve their home. In the current property market, people are more likely to do this than move as there is so much uncertainty.
Participating architects can give general advice on:
. Architect's fees and services
. Information on building costs including VAT
. Discussion on building materials likely to be used
. Planning requirements or Exempted Development from Planning
. The documents that will be used for planning; tenders; and
building contracts
Due to the time constraints inherent in an hour long consultation, it won't be possible to receive specific planning advice or an actual design from the Architect.
Kathryn says that the more preparatory work done prior to the consultation, the more people will get out of it.
What should people bring to their consultation?
The Architect will need to know specific requirements so, if possible, please bring:
. Ordnance Survey Map; or Lease Map; or Site Location Map
. Photos of the elevations of your house (front and rear) and
adjoining houses
. General Site Dimensions and the approximate area for the
proposed development (especially important if you want to have
building work done in back and side gardens)
. Rough idea of your budget (it should include VAT, fees, furniture
and landscaping if applicable)
. Brief description of what you want i.e. do you want an extra
bathroom in your extension; a new garage; an additional
bedroom etc; special facilities for those with disabilities?
. Has the dwelling obtained planning permission or been previously
extended.The more information you bring with you the more you will get out of your consultation.
Who should avail of this service?
Prospective buyers can avail of the service to check feasibility of potential purchases. If you bring property brochures etc along to the consultation, the architect can discuss future potential of the property or problems if the case may be.
People who are intending to build their own home can visit with an architect to get fresh ideas or suggestions on building an environmentally sustainable house, an aesthetically interesting house or perhaps how to maximize space in a small new-build.
People who wish to extent their homes and are seeking suggestions on how best to do this in an economical and design effective manner. Space is at a premium at present and people are keen to extend rather than move- architects can suggest how you could achieve a second bathroom/attic conversion etc.
Those living in apartments could get storage suggestions in order to maximize their smaller living spaces.
Can adapting to a "greener" home add to the value of the property?
All homes will soon be subject to energy ratings and sustainable building regulations. This will influence the sale of second hand homes more and more in the years to come.
There are an estimated 5,500 homeless people in Ireland although the Simon Community says that these figures are based on homeless people who have contacted local authorities only, therefore the real figure is higher.
Top five tips be for people wishing to avail of this service:
1. Be open-minded - and unrestrained in your thinking. Listen to your architect's ideas; they are experts and might see possibilities you haven't considered.
2. Be prepared - bring scale plans or photographs of your home or site, know which way is north.
3. Be forward-thinking- consider what your changing family will need from your home as you get older. This is called designing for a "Lifetime Home."
4. Be green- your architect can advise you on environmentally friendly ideas for your design plans. Thinking green can help you save money and the environment
5. Be realistic- an hour is a short amount of time. Prioritise what you want to cover.
"Given recent changes in the housing market people are looking at options other than moving to meet the changing needs of their families - whether it's the open plan kitchen you always dreamed of or an additional family room, a home office or even that large bedroom with a walk in wardrobe an RIAI architect brings vision and imagination to projects of all shapes and sizes"
Sean O' Laoire, President of the RIAI
Following are more tips to help you get the most from your consultation:
1. Be clear- getting your project right at the start will save you money in the long term. If you don't understand something, ask the architect to draw you a 3-D sketch to help you visualise the plans.
2. Be practical- tell the architect about your dream home, but also about your budget.
3. Be aware- your architect can give you both design and technical advice about planning applications rules and procedures and compliance with building and fire regulations!
4. Be relaxed - don't be intimidated- your architect is there to help. Ask what's possible, how long will it take, how much will it cost etc
Be assured the architect you are speaking to is held to the highest standards -
20 Questions to ask yourself before you get started on your project:
1. Describe your current home
What do you like about it?
What's missing?
What don t you like?
2. Do you want to change the space you have?
3. Do you want to build a new home?
4. Why do you want to build a house or ad to or renovate your current home?
5. What is your lifestyle?
Are you at home a great deal?
Do you work at home?
Do you entertain often?
How much time do you spend in the living areas, bedroom, kitchen, utility space, etc?
6. How much time and energy are you willing to invest to maintain your home?
7. If you are thinking of extending, what functions/activities will be housed in a new space?
8. What kind of spaces do you need, eg. bedrooms, bigger kitchen, family room, bathrooms, etc?
9. How many of those spaces do you think you need?
10. What do you think the extension/renovation/new home should look like?
11. What do you envisage in your new home that your present home lacks?
12. How much can you realistically afford to spend? In your budget you should include VAT, and Architects Fess plus VAT. Do you wish to include decoration, furniture and
fittings, landscaping or special facilities?
13. How soon would you like to be settled into your new home or extension? Are there rigid time restraints?
14. If you are thinking of building a home, do you have a site selected?
15. Do you have strong ideas about design? What are your design preferences?
16. Who will be the primary contact with the architect, contractor, and others involved in designing and building your project? (It is good to have one point of contact to prevent confusion and mixed messages)
17. What design qualities are you looking for from your architect?
18. Is there anyone in the family with a disability, or do you envisage staying in the house for a long time so that the mobility problems of aging may need to be addressed.
19. Is sustainable development and increased energy efficiency of importance to you?
20. How much disruption in your life can you tolerate to extend or renovate your home?
For more information check out www.simonopendoor.ie
email@example.com Tel: 0818 300151


text:
Botsford News Release
Farmington Hills, Mich. (April 19, 2012)---David Gaffney has been hired to serve as Botsford Hospital's new director of medical imaging. He began this position April 17.
Gaffney has responsibility over the Botsford Imaging Center, a newly renovated and technologically advanced facility that includes magnetic resonance imaging (MRI), computer tomography (CT), digital mammography, x-ray, ultrasound and nuclear medicine.
He comes to Botsford Hospital from Henry Ford Macomb Hospital-Warren Campus where he had been serving as director of medical imaging since 2006. Gaffney's 22-year work experience also includes radiologic positions at Sinai-Grace Hospital, Providence Hospital and the former St. Joseph Mercy Hospital Macomb, now part of Henry Ford Health System.
Gaffney holds a master of business administration degree from University of Detroit Mercy and a bachelor's degree in radiology from St. Mary's College. He is certified as a registered radiologic technologist by the American Registry of Radiologic Technologists. Gaffney also has administrative certification from the American Healthcare Radiology Association.
Beaumont Health is Michigan's largest health care system, based on inpatient admissions and net patient revenue. A not-for-profit organization, it was formed in 2014 by Beaumont Health System, Botsford Health Care and Oakwood Healthcare to provide patients with the benefit of greater access to extraordinary, compassionate care, no matter where they live in Southeast Michigan. Beaumont Health consists of eight hospitals with 3,337 beds, 168 outpatient sites, nearly 5,000 physicians and 35,000 employees and about 3,500 volunteers. In 2015, the organization had $4.1 billion in net revenue with 177,934 inpatient admissions, 17,151 births and 530,860 emergency visits. For more information, visit beaumont.org.
botsford.org, twitter, facebook, blog
MEDIA CONTACT: Lynn C. Anderson, Director, Marketing & Public Relations or Beth Montalvo, Publications & Media Relations Coordinator
Download Attachments: David Gaffney.JPG


text:
The buy to let market has been in the media a lot recently, and more and more people are considering this form of investment. However, like any investment, it needs to be approached with caution, and appropriate advice should always be sought.
If you are interested in buy to let, or indeed are already a buy to let investor, you might find it useful to consider these points:
The Property
When considering a buy to let property, some key issues are the location, nature and style of the property you hope to lease out. At this point I would emphasise that your own personal taste and preferences in relation to location and property styles should be taken out of the equation. You need to establish your financial aims and goals. Various sectors of the rental market provide different results – some sectors will provide minimal or nil capital growth, but will offer a reasonable return or yield, whilst other sectors may potentially in the long term provide capital growth, although the yield may be disappointing. You will have to take into account whether your move into the buy to let market is a short, medium or long-term scenario, and whether your aim is to achieve an ongoing monthly source of income or a long-term investment for future gain.
Your decision on property also has to include the level of investment, and as such the potential number of properties in your portfolio. Do you buy one property at £330,000 or three properties at £110,000? The actual purchase/investment cost, running cost, possible returns, legislative and regulatory requirements and the risks are potentially different. These factors need to be investigated and understood.
As with any business, how the business is to be funded and returns dealt with must be established. Decisions have to be made as to the extent of personal outlays and borrowings that will be required. In many cases specialist advice is needed in order to obtain loan funding for a buy to let property. The majority of lenders will view this as a business scenario restricting the terms and life of the loan. It should be noted that if you are proposing to lease your current home there will be a requirement to inform your lender, who may not support the proposal on your current mortgage package.
In working on your financial plan you must also remember to take tax into account, as this will potentially fall into various categories depending on a mixture of situations relating to the property and your personal circumstances – this is an area where seeking appropriate advice is particularly necessary.
In addition professional input should definitely be considered if there is more than one investor, particularly if the investment percentage amounts differ.
Void Periods
A factor that many fail to take into account is that while in an ideal world the property remains leased for the full term of any loan, the reality is in the ever-changing market there may be void periods in between lease agreements where there is no rental return. Some consider a spread of properties safer to minimise the impact of one property being vacant. It is essential that this be factored into the decision process. There are products in the market which can allow you to effectively insure against void periods.
The nature of the property, the capital outlay and the location will to an extent dictate the nature of the tenants, although careful consideration will also be required to establish the type of tenant you would prefer to occupy your property, and by default the risk of damage. You should also remember that (if it is your former home) tenants may not treat the property in the same way as you did. You must remember that this is a business decision and keep emotion out of the equation.
As with any business, there are multiple rules, regulations and statutory requirements that must be met. You need to decide whether you will engage the services of a letting agent (who will, of course, charge for their time), or alternatively whether you will allow a budgeted cost for your personal time, to ensure that you comply with all the regulations in conjunction with the ongoing maintenance problems that relate to a rental property.
It is a requirement, for example, that you register as a landlord with the local authority where the property is located. Failure to do this could mean a hefty fine.
Protecting Your Assets
As you work on your plan you need to keep in mind that the world is not fair and not everything goes according to plan. It is advisable to protect yourself, your family, and your assets.
This may in some cases be as simple as writing or reviewing your will, but setting up companies and trusts might also be considered. Again, advice should be sought as to the best solution for your circumstances.
Again it should be emphasised – this is a business. Remember that it does not matter who you are leasing to – whether they are a family member, friend or stranger, you need to have a formal lease signed from the outset. This helps prevent future problems. If the property is mortgaged, your lender will insist on a formal lease.
Business Planning and Budgeting
If you fail to plan and to run your buy to let business as such, then you can very easily run into serious difficulties. It is strongly recommended that anyone considering a buy to let investment seek appropriate advice from the outset, in order to be aware of all the potential costs, outlays, pitfalls and risks at play, and to prepare an appropriate business plan and budget to take these into account. With proper preparation and planning the risks can be minimised, and buy to let property can be a very successful investment.


text:
Nottinghamshire bowler Ryan Sidebottom took two wickets as England beat Australia to be crowned ICC World Twenty20 Champions.
Sidebottom was one of five Notts players to feature in the match with Graeme Swann claiming the prized wicket of Michael Clarke.
David Hussey, who will join Notts in early June, top-scored for Australia with 59 before he was athletically caught by Stuart Broad.
Needing 148 runs to win, Craig Kieswetter (63) and Kevin Pietersen (47) helped England cruise to their target with three overs to spare.
"I've had a great week and it's due to the efforts of all of the lads", said Kevin Pietersen who scored 238 runs in the tournament.
"It's so good to be part of a dressing room where everybody works hard and is deserving of this success.
"This team is hungry for success and we work hard and strive for success in every training session.
"Playing against Australia is never easy because they have got some fantastic bowlers. You have to try and target every bowler and we got the better of them today."
Dirk Nannes was the leading wicket-taker in the tournament with 14 and will arrive in Nottinghamshire on Wednesday to train with his new team mates ahead of the Friends Provident t20.


text:
Your Paper Your Way
We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.
To find out more, please visit the Preparation section below.
The Journal of Allergy and Clinical Immunology: In Practice covers the spectrum of conditions treated by allergist-immunologists in their practice: asthma, allergic bronchopulmonary aspergilosis, hypersensitivity pneumonitis, allergic and nonallergic rhinitis, nasal polyps, chronic sinusitis, urticaria and angioedema (including /HAE), atopic dermatitis, contact dermatitis, anaphylaxis, food allergy, drug allergy, insect sting allergy, mast cell disorders, ocular allergy, eosinophilic gastrointestinal disorders, and immune deficiency. It also covers symptoms and signs for which patients are referred to the allergist-immunologist, such as cough, pruritis, rash, dyspnea, and eosinophilia. The emphasis of the journal is on practical information for clinicians that they can use in everyday practice or that will help them acquire new knowledge or skills they can directly apply to their practice. Mechanistic or translational studies without immediate or near future clinical relevance are discouraged.
Article types
The Journal will consider publication of several types of manuscripts:
Each Original Article will be accompanied by a highlights box that provides bulleted answers to the following questions (each answer should be no longer than 35 words):
1. What is already known about this topic?
2. What does this article add to our knowledge?
3. How does this study impact current management guidelines?
B. Clinical Communications. Clinical Communications are brief reports of clinical or laboratory observations or case series. Single case reports will only be considered if they demonstrate a novel, impactful insight, rather than simply an educational point. Clinical Communications are limited in scope, and without sufficient depth of investigation to qualify as Original Articles. Like Original Articles, these manuscripts are subject to peer review.
A Clinical Communication must:
(1) Be brief. A Clinical Communication should not exceed 1,000 words, not including the figure legend(s) and references. The figure legend(s) should be held to 60 words or less. Please note: Clinical Communication manuscripts that are determined to exceed these limits will be returned to the authors for shortening prior to review.
(2) Have a short, relevant title.
(3) Have a complete title page.
(4) Present a list of Key words, as relevant.
(5) Provide 1-2 sentences (maximum 40 words) that summarize the clinical implications and importance of the report to be used in a Clinical Implications box published at the beginning of the article.
(6) Begin with the salutation "To the Editor:"
(7) Have no more than nine references.
(8) List the references as complete bibliographic citations following the closure of the letter.
(9) Be limited to a total of 2 figures and/or tables. (Additional figures or tables may be placed in the article's Online Repository; please see the relevant section below.)
D. Correspondence and Replies. Correspondence concerning recent publications in JACI: In Practice will be considered for publication and accepted based on their pertinence, their scientific quality, and available space in the Journal. If the correspondence is considered acceptable, a response will be requested from the authors of the referenced JACI: In Practice article. Upon review and approval by the Editor, the Correspondence and relevant Reply will both be published together.
Both Correspondence and Reply manuscripts must:
(1) Be no longer than 500 words.
(2) Have a short, relevant title, distinct from the title of the referenced article. Please note that all Replies should have the title "Reply to [Corresponding author's name]."
(3) Have a complete title page.
(4) List the references as complete bibliographic citations at the end of the letter with the journal article being discussed as the first reference. The total number of references should be no more than seven. Replies should include the Correspondence to which they are replying as one of the references.
(5) Have no more than one graphic presentation (table or figure).
(6) Begin with the salutation "To the Editor:".
F. Rostrum articles. Opinion articles about subjects of particular interest and/or debate may be accepted for peer review after preliminary review by the Editor. Proposals for rostrum articles may be emailed to the Editorial Office (email@example.com); they will be evaluated based on level of interest, novelty, and the current needs of the Journal.G. Practice Options from Beyond Our Pages. This feature is focused on identifying, critiquing, and placing into context research studies that have the potential to change our clinical practices. Published studies beyond the pages of the Journal of Allergy and Clinical Immunology: In Practice and the Journal of Allergy and Clinical Immunology that have a high likelihood of changing practice NOW should be the focus of submissions in this series. Articles to consider are meta-analyses, randomized double-blind placebo-controlled trials, effectiveness studies, new diagnostic breakthroughs, etc.
Who should submit: The Journal of Allergy and Clinical Immunology: In Practice is seeking Allergy-Immunology Fellows-In-Training partnered with faculty members to submit an article of 1000 words or less.The article's title should be a succinct description of the major topic and the potential practice change. The manuscript text should be arranged in the following format:
"Practice Options Beyond From Our Pages" contributions should adhere to the "Guide for Authors" of the Journal of Allergy and Clinical Immunology: In Practice for bibliographic style, general format, and other matters.
Reference: The study that is being reviewed (see web site for accepted bibliographic style).
Background: The authors should clearly state the current clinical practice and/or guideline and how this study has the potential to change the current practice.
Methods: Summary of the methods used in the study that is being reviewed.
Results: Summary of the main results. (Possibly include a small table. Please note that permissions would need to be obtained for any tables reproduced from the original study).
Critical appraisal: The authors should discuss any major limitations of the study and how they influence the potential to translate the findings into practice. Comparisons with previous studies that addressed similar practice questions should be considered and appropriately cited in a reference list at the end of the manuscript.
Recommendation: The authors should briefly state the recommended practice change.
Authors do not require an invitation to submit. Submission does not guarantee publication. Suggestions for revisions may be made before the contribution is considered acceptable.H. Practice Pearls.This is a feature that promotes sharing of clinical wisdom among practicing allergist-immunologists. A "Practice Pearl" is something that helps an allergist-immunologist practice more safely, effectively, timely, efficiently, equitably, or in a more patient-centered, way. A "Practice Pearl" is generally not a case report of a very unique situation and is not based on a formal study, but is rather a solution to a practical challenge that is developed by the submitter and can be applied by allergist-immunologists to help many patients.
Submissions should be structured into 2 sections: (1) Practice challenge and (2) Practice solution. Submissions should be no longer than 300 words and inclusion of up to 2 illustrations (figures or tables) and 2 references are optional. Audio and video on-line supplements are encouraged. Submissions will be peer-reviewed prior to acceptance.Submission checklist
You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.
Ensure that the following items are present:One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address
All necessary files have been uploaded:
• Include keywords
• All figures (include relevant captions)
• All tables (including titles, description, footnotes)
• Ensure all figure and table citations in the text match the files provided
• Indicate clearly if color should be used for any figures in print
Graphical Abstracts / Highlights files (where applicable)
Supplemental files (where applicable)
• Manuscript has been 'spell checked' and 'grammar checked'
• All references mentioned in the Reference List are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Internet)
• A competing interests statement is provided, even if the authors have no competing interests to declare
• Journal policies detailed in this guide have been reviewed
• Referee suggestions and contact details provided, based on journal requirements
For further information, visit our Support Center.
Ethics in publishing
Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication.
If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans; Uniform Requirements for manuscripts submitted to Biomedical journals. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.
All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed.Conflict of Interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. The Journal requires all authors to acknowledge, on the title page of the manuscript, all funding sources that supported their work. Authors are also required to disclose to the Editor, in separate signed documents, any commercial associations that might pose a conflict of interest. These include consultant arrangements, speakers' bureau participation, stock or other equity ownership, patent licensing arrangements, support such as financial or materials grants for research, employment, or expert witness testimony. See also http://www.elsevier.com/conflictsofinterest. Further information and an example of a Conflict of Interest form can be found at: http://service.elsevier.com/app/answers/detail/a_id/286/supporthub/publishing.
If the paper is accepted for publication, disclosure of any such associations will be published as a footnote to the article. No article can be published in the Journal unless a signed and completed Conflict of Interest statement has been received from each author. JACI: In Practice uses the International Committee of Medical Journal Editors (ICMJE) Form for Disclosure of Potential Conflicts of Interest. A copy of the form can be downloaded from the EES Web site (http://ees.elsevier.com/inpractice/).Required documents
Conflict of Interest disclosures and permissions forms (when applicable) must be received in the Editorial Office before an accepted manuscript can be sent to the publisher. These forms can be uploaded electronically with your manuscript submission, or sent via email to the Editorial Office (firstname.lastname@example.com). A template of the Conflict of Interest form is available for downloading from the EES Web site (http://ees.elsevier.com/inpractice/img/Forms.html). (If you are submitting your Conflict of Interest disclosure forms to us as part of your electronic submission in EES, please be sure to include all of these forms with each subsequent version of your manuscript.)
Permission to reuse previously published material/informed consent releases
If applicable, authors of manuscripts submitted to JACI: In Practice must provide the Editorial Office with proof of permission to reuse any previously published material that has appeared in another publication. Additionally, in the case of photographs of identifiable persons, a signed release showing informed consent must be provided. Because articles appear in both the print and online versions of the journal, wording in the permissions form/release should specify "permission to publish in all forms and media." Written permission to reuse the specified material can be uploaded with the manuscript submission or forwarded to the Editorial Office by email (email@example.com) or fax (319-467-7583). Acceptance of a manuscript is conditional upon receipt of permission.
Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see 'Multiple, redundant or concurrent publication' section of our ethics policy for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck.
Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.
Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.
Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The CONSORT checklist and template flow diagram are available online.
Special instructions regarding statistical analyses and reporting
1. METHODS: Reporting on Statistical Methods. The Consolidated Standards of Reporting Trials (CONSORT) statement is a set of guidelines for reporting on the methods and results of randomized and nonrandomized medical research studies.
• With respect to item 12, the statistical methods and commercial software should be cited.
• Item 7 and item 12 of the checklist are relevant to the Statistical Methods section of a manuscript submitted to JACI: In Practice based on a nonrandomized study. Thus:
Items 13 through 19 of the CONSORT checklist describe items that are important to the Results section for a manuscript submitted to JACI: In Practice based on a RCT (some of the items might not be relevant if the study is nonrandomized). Thus:
2A. Results: Descriptive Statistics at Baseline
If the distribution for a continuous variable is approximately normally distributed, then report either
• the sample mean and the sample standard deviation or
• the sample mean and the 95% confidence interval for the population mean.
If the distribution for a continuous variable is known (or suspected) to be nonnormal, then report either
•the sample median and the sample interquartile range or
• the sample median and the sample first and third quartiles.
Many blood and urine measurements are log-normally distributed-i.e., the logtransformed variable is approximately normally distributed. If the distribution for a continuous variable is known (or suspected) to be lognormal, then an alternative to sample medians and quartiles is to report either
• the sample geometric mean (calculate as the exponentiation of the sample mean of the natural log-transformed data) and the sample coefficient of variation or
• the sample geometric mean and the 95% confidence interval.
If the distribution of the variable is categorical, then report the raw numbers and the percentages for the categories. Do not use more than three digits for the percentages-i.e., 79% or 79.3% are fine, but 79.32% is not.
Statistical tests, along with reported P values, for comparing groups at baseline are not necessary unless there is a strong reason to include them.
2B. Results: Outcomes
• Every P value should be reported using two digits after the decimal point. If each of the first two digits after the decimal point is zero, then a third digit can be used. If each of the first three digits after the decimal point is zero, then simply report P < .001.
• If the P value is close to the level to be used for claiming a statistical significance or if each of the first two digits after the decimal point is zero, then a third digit can be used. For example, if the significance level is 0.05, then P = .046 or P = .054 can be reported. Nonsignificant results (e.g., where the P value is > 0.05) should be accompanied by P values; it should not simply be stated that they are nonsignificant (NS).
• P values alone are not sufficient to report the results of statistical tests. JACI: In Practice's readers need to see the magnitude of the effects via point estimates and 95% confidence intervals for the group comparisons.
An estimate of odds ratios and relative risks (and their corresponding confidence interval estimates) should not exceed two digits beyond the decimal point.
The following is an excellent article that discusses the reporting of subgroup analyses in clinical research: Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine-reporting of subgroup analyses in clinical trials. NEJM 2007;357:2189-2194.Finally, if authors desire more detailed guidance on appropriate methods for analyzing study outcomes, then they can visit the Web sites of other biomedical journals. An excellent example is the Web site of the Annals of Internal Medicine (http://www.annals.org/shared/author_info.html).
Statements and opinions expressed in the articles and communications in the Journal are those of the author(s) and not necessarily those of the Editor(s) or publisher, and the Editor(s) and publisher disclaim any responsibility or liability for such material. Neither the Editor(s) nor the publisher guarantee, warrant, or endorse any product or service advertised in this publication, nor do they guarantee any claim made by the manufacturer of such product or service.Adherence to key guidelines
JACI: In Practice endorses the following guidelines and encourages authors to make every attempt to conform to their recommendations:
STROBE statement for observational studies
When preparing observational reports, we encourage authors to review the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) Statement, available at www.strobe-statement.org.
For meta-analysis of RCTs, we encourage authors to consult the recommendations of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement, available at www.prisma-statement.org.
STARD statement for diagnostic studies
For reports of diagnostic studies, we recommend the STARD (Standards for Reporting of Diagnostic Accuracy) Statement, available at www.stardstatement.org.
This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. More information.
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.
For open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (more information). Permitted third party reuse of open access articles is determined by the author's choice of user license.Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. More information.
Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.
Note regarding National Institutes of Health-sponsored research: JACI: In Practice's publisher, Elsevier, facilitates author posting in connection with the posting request of the NIH (referred to as the NIH "Public Access Policy"; see http://publicaccess.nih.gov/). If an author indicates that the research reported in their article was sponsored by the NIH, either by checking the appropriate box on the Transfer of Copyright form or by completing the relevant field during the online submission process, Elsevier will send the accepted version of the manuscript to PubMed Central (PMC) for public access posting 12 months after final publication. Please note that the accepted version of the manuscript does not include changes that are made during the review of galley proofs. For more information about PubMed Central, please visit http://www.ncbi.nlm.nih.gov/pmc/about/faq/.
Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the Open Access Publication Fee. Details of existing agreements are available online.
After acceptance, open access papers will be published under a noncommercial license. For authors requiring a commercial CC BY license, you can apply after your manuscript is accepted for publication.
Open access
This journal offers authors a choice in publishing their research:
• Articles are freely available to both subscribers and the wider public with permitted reuse.
• An open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.
• Articles are made available to subscribers as well as developing countries and patient groups through our universal access programs.
• No open access publication fee payable by authors.
Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.For open access articles, permitted third party (re)use is defined by the following Creative Commons user licenses:
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.
The open access publication fee for this journal is USD 3300, excluding taxes. Learn more about Elsevier's pricing policy: http://www.elsevier.com/openaccesspricing.
Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our green open access page for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. Find out more.
This journal has an embargo period of 12 months.
Language services
Please write your text in good American English. Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop, http://webshop.elsevier.com/languageediting/, or visit our customer support site, http://support.elsevier.com, for more information.
Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail. For instructions regarding how to use the submissions site, please visit http://support.elsevier.com/app/answers/detail/a_id/116.
Submit your article
Please submit your article via http://ees.elsevier.com/inpractice.
Please submit the names and institutional e-mail addresses of several potential referees. For more details, visit our Support site. Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.
The title page, abstract, key words, abbreviations, text, acknowledgments, references, tables, and figure legends should be included in a single file (.doc or .docx format). Figures should be loaded as separate files in the format specified below.
Basic formatting
All sections should be double-spaced. On each page, the last name of the first author and the page number should appear in the upper right corner. Begin numbering with the title page as page 1. Be sure to display line numbers (1, 2, 3, and so forth) in the left margin of the manuscript. The line numbering should be continuous throughout the entire manuscript, from the title page through final page (i.e., do not begin numbering from 1 again at the top of each page).
Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.
As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or lay-out that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.
There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript. If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.
Divide the article into clearly defined sections.
Figures and tables
Figures should be uploaded each as separate Figure files, with the figure legends placed in the manuscript file, after the reference list. Tables can either be placed in the manuscript file, after the reference list and figure legends (if applicable), or uploaded as a separate Tables file. Please see the Artwork section for specific formatting information for Figures. Tables need to be created using Microsoft Word's Tables function, and uploaded a .doc file(s).
Use of word processing software
Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). See also the section on Electronic artwork.
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.
Subdivision - unnumbered sections
Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading should appear on its own separate line. Subsections should be used as much as possible when cross-referencing text: refer to the subsection by heading as opposed to simply 'the text'.
Please consider the following guidelines:
• Keep the title succinct: Limit it to 12 words or fewer.
• Communicate a single subject or idea in the title.
• Construct the title around the article's key words.
• Include the specific symptom, condition, intervention, mechanism, or function of the paper's central focus.
• Mention any defining population, age, gender, or animal species that distinguishes the work.
• Use terms that are specific rather than general (e.g., "penicillin" rather than "betalactam antibiotic") and include terms that clarify (e.g., "CXCR4" rather than "chemokine receptors").
• Avoid using strong words (such as "robust," "innovative," "significant," "vigorous," and "aggressive"), as they may suggest exaggerated or unwarranted claims.
• Use wit carefully and appropriately; be informative first and clever second. Although a universally understood pun can work well to attract interest, ensure that it will not confuse or mislead the reader.
• The titles of papers accepted for publication in the Journal of Allergy and Clinical Immunology: In Practice may be revised for improved clarity and appeal to the readership. Such revision will have final approval by the authors.
State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.
Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.
Results should be clear and concise.
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.
Essential Title Page Information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
• Author names and affiliations. Include full names, highest academic degrees, and institutional affiliations. Please note:
(A) To be listed as an author, an individual must meet the requirements approved by the International Committee of Medical Journal Editors (ICMJE). In order to be included in the list of authors, an individual must have done all of the following: (1) made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafted the article or reviewed it critically for important intellectual content; and (3) given final approval of the version to be published.
(B) The Journal of Allergy and Clinical Immunology: In Practice (JACI: In Practice) does not allow "ghostwriting," or uncredited authorship. All writers of a manuscript should be clearly identified. Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author. (Note: A different author may be designated as the Corresponding Author in EES for the duration of the submission and review processes.)
• Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
For original articles, the abstract should be no longer than 250 words. It should summarize the results and conclusions concisely. Tabular data should not be included and acronyms/abbreviations should be avoided or spelled out fully. Abstracts should be structured as follows:
• Background: What is the major problem that prompted the study?
• Objective: What is the purpose of the study?
• Methods: How was the study done?
• Results: What are the most important findings?
• Conclusion: What is the most important conclusion drawn?
Review articles follow an unstructured abstract.Keywords
Before the manuscript text in Original Articles, provide a maximum of 10 keywords (following the Highlights box), using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.
Provide a list of any abbreviations/acronyms and their definitions following the key words. Only standard abbreviations are to be used. If you are uncertain whether an abbreviation is considered standard, consult Scientific Style and Format by the Council of Science Editors or the AMA's Manual of Style. A laboratory or chemical term or the name of a disease process that will be abbreviated must be spelled out at first mention, the acronym or abbreviation following in parentheses.
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here the full names of those individuals who provided help during the research (e.g., consultations, statistical analyses, providing language help, writing assistance or proof reading the article, etc.). Only acknowledgment of funding should be listed on the title page.
Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder's requirements:
It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.If no funding has been provided for the research, please include the following sentence:
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Units
Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.
Math formulae
Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.
The total number of graphic presentations (tables and/or figures) per manuscript should comply with the limits for the manuscript's Article Type; requests to include additional graphics must be approved by the Editors.
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar. Keep a consistent font size throughout each figure, and for all figures.
• Number the illustrations according to their sequence in the text.
• Images need to be easily readable with good contrast, particularly figures that have multiple parts and/or a lot of different symbols or components. Clarity and consistency should be uniform among the parts of a multi-part figure, and among all the figures in a manuscript.
• In colorizing your figure(s), we ask that you keep in mind that some of our readers are colorblind and may be unable to distinguish different colors easily. To accommodate these readers, we suggest that you consider some type of aid, such as labeling each column of a bar graph with an identifier or providing a key with differently shaped symbols to identify each set of data. It is also helpful to use colors of varying intensity so that they are distinguishable as different shades of gray when viewed by the colorblind. It is important that you submit all figures in the dimensions in which they are to be published in the journal. They must be sized to the smallest dimensions that allow legibility and clarity without undue use of space.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the printed version.
• Submit each illustration as a separate file.
A detailed guide on electronic artwork is available on our website:
You are urged to visit this site; some excerpts from the detailed information are given here.
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.
Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.
Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Indicate per figure if it is a single, 1.5 or 2-column fitting image.
• For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
• Please note that individual figure files larger than 10 MB must be provided in separate source files.
A detailed guide on electronic artwork is available.
You are urged to visit this site; some excerpts from the detailed information are given here.
Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.
TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.
Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
• Supply files that are too low in resolution.
• Submit graphics that are disproportionately large for the content.
Please make sure that artwork files are in an acceptable format (TIFF [or JPEG], EPS [or PDF] or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g., ScienceDirect and other sites) in addition to color reproduction in print. This specifically applies to Original Articles, Review Articles, Images and Allergy, and any figure that is included on the first or second page of a Clinical Communications article. For other article types or additional figures in the Clinical Communications section, these figures can be included with payment of a fee; the publisher will contact the authors following acceptance of the manuscript to discuss the relevant costs and payment details. If illustrations appear in the manuscript, they must be submitted in electronic format along with the rest of the manuscript. For further information on the preparation of electronic artwork, please see http://www.elsevier.com/artworkinstructions.
Illustration services
Elsevier's WebShop offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.
Figure legends should be listed in the manuscript file, on a separate page after the tables. They should not appear in the figure files. The figure legend will be included when sizing the figure and its length must therefore be taken into consideration. The figure title should appear at the beginning of each legend. The legends themselves should be succinct (no more than 60 words), identifying the data or subject being presented, but not explaining methods or results.
Figure captions
Ensure that each illustration has a caption. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.
If tables appear in the manuscript, they must be included in the electronic submission. They may be placed within the manuscript file or loaded as separate files (in .doc or .docx format). Tables should supplement, not duplicate, the text; they should be on separate pages, one table per page, and should be numbered with Roman numerals in order of mention. A brief title should be provided directly above each table. Any abbreviations should be defined at the bottom of the table. When creating a table, use the wordprocessing program's table formatting feature; otherwise, use only tabs (not spaces) to align columns. Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.
Reference links
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.
Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.
References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:
Reference style
It is the Editors' expectation that authors will perform a comprehensive search of the literature to gather the most current articles relative to the subject matter. Citing abstracts as references is strongly discouraged. An abstract should only be included as a reference if the evidence it provides is important to the manuscript and exists nowhere else in citable form. Abstracts that are included in the reference list must be bolded so that reviewers can easily identify them and evaluate their appropriateness.
(1) Using the "Select All" feature (Ctrl-A for PCs. Cmd-A for Macs), highlight the entire text of the file, including the references.
(2) Use the keystroke command Ctrl-6 for PCs or Cmd-6 for Macs.
(3) Save. This will remove the links (permanently) without disturbing the reference numbers or the citations. It is recommended that you save one copy of your manuscript with the EndNote links in place (for your reference) and one copy of your manuscript without the EndNote links (for submission purposes).
Examples of Reference FormattingJournal article:
Parkin DM, Clayton D, Black RJ, Masuyer E, Friedl HP, Ivanov E, et al. Childhood leukaemia in Europe after Chernyobyl: 5-year follow-up. Br J Cancer 1996;73:1006-12.
Ringsven MD, Bond D. Gerontology and leadership skills for nurses. 2nd ed. Albany (NY): Delmar Publishers; 1996.
Phillips SJ, Whisnant JP. Hypertension and stroke. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press; 1995. p. 465-78.
Internet resource:
US positions on selected issues at the third negotiating session of the Framework Convention on Tobacco Control. Washington, DC: Committee on Government Reform; 2002. Available at: http://www.house.gov/reform/min/inves_tobacco/index_accord.htm. Accessed March 4, 2002.
Journal names should be abbreviated according to the list of title word abbreviations: http://www.issn.org/2-22661-LTWA-online.php.
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 150 MB in total. Any single file should not exceed 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.
The Journal will consider posting ancillary materials (non-essential text, tables, figures, videos, appendices, questionnaires, etc.) in an Online Repository (OR). The OR is for peer-reviewed material that cannot be included in the print version of an article due to space considerations. In the manuscript text, materials that are housed in the OR must be referenced specifically (e.g., "see Figure E1 in the Online Repository"). Note: OR material consisting of 15 pages or less is built directly into the downloadable PDF of the published article; for material longer than 15 pages, a link is provided in the online version of the article.
On an individual basis, the Editors will determine whether ancillary material submitted in support of a manuscript is warranted. In some instances, an Editor may suggest when requesting a revision that part of the data be presented for the OR and removed from the manuscript, perhaps at the request of the reviewers.The ancillary material must be submitted in EES simultaneously with the rest of the manuscript. The OR material should be loaded as separate files, and should follow the end of the regular manuscript. For revisions that will include newly designated OR material, the Marked Manuscript should show where materials were removed from the original version, and include appropriate statements directing readers of the article in the print journal to the OR. The Unmarked Manuscript will reflect the latter changes.
Guidelines for Online Repository text:
• All text files for the OR should be formatted per directions for regular manuscript materials.
• If citations are made within the ancillary material, a list of references, separate from the manuscript's references, must be included and labeled E1, E2, etc.
• Authors may repeat sentences or references in the OR that are included in the manuscript, if necessary for reader comprehension.
• Tables for the OR should be submitted as files with any of the following extensions: doc, .csv, .txt,.rtf, .xls, or .ppt. The tables must have been created in the same format that they are saved, so that they can be copyedited if needed.
• Figures for the OR do not need to conform to the print specifications for resolution, but they do need to appear clear and crisp when viewed electronically.
• Figures and Tables must be designated as Figure E1, Table E1, etc, and should be numbered separately from the illustrations in the manuscript proper.
Revision of manuscripts
As with new submissions, revisions must be submitted electronically through EES. Ensure that the revised manuscript is prepared in accordance with the Journal's format and style for the type of article being revised. Please refer to the "User Guide for Authors" (http://support.elsevier.com/app/answers/detail/a_id/116) for additional information. Adherence to these guidelines is important to prevent a delay in processing the revised manuscript. Please note: Graphic presentations (i.e., tables, figures, and Online Repository files) are not automatically included in the revised submission. Be sure to include all files that should be considered for publication with your revised submission.
(1) A Responses to Comments document that includes point-by-point responses to the comments made by the Reviewers, Editor, and Editorial Office. In your Responses to Comments document, reproduce each comment verbatim and in its entirety and follow the comment with your detailed response. Each of the comments should be preceded by the word "COMMENT," and the font style for each comment should be bold. Each of your responses should be preceded by the word "RESPONSE," and the font style for each response should be regular (not bold). In each response, indicate where relevant changes have been made in the manuscript or explain why no changes would be appropriate. If any alterations have been made to your figures or if any figures have been removed or replaced, describe the changes.
(2) A Marked Manuscript. The Marked Manuscript should be a version of your revised manuscript in which all of the ways in which it is different from the original manuscript are indicated for the sake of the Editor. The preferred method of indicating changes is Microsoft Word's Track Changes feature. Alternately, any text that has been added should be underlined, and any text that was deleted should be indicated by strikethrough formatting. Any table that was part of your original submission should be either embedded within the Marked Manuscript or provided as a separate file (e.g., "Table II - Marked"); if changes have been made to the table, they should be indicated. Likewise, any figure that was part of your original submission should be either embedded within the Marked Manuscript or provided as a separate file (e.g., "Figure 1 - Marked"); if changes have been made to the figure, they should be described in your Responses to Comments document. Line numbering (continuous) should be used throughout the Marked Manuscript.
(3) An Unmarked Manuscript. The Unmarked Manuscript should be your revised manuscript just as you intend it for publication (if it is accepted). Any table that is to be part of your revised manuscript should be either embedded within the Unmarked Manuscript or provided as a separate file (e.g., "Table II - Unmarked"). Any figure that is to be part of your revised manuscript must be provided as a separate file (e.g., "Figure 1-Unmarked").
(4) Conflict of Interest Disclosure forms. If you are submitting your Conflict of Interest disclosure forms to us as part of your electronic submission in EES, please be sure to include all of these forms with each subsequent revision of your manuscript. Proofs
One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author, or a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download Adobe Reader version 7 (or higher) available free from http://get.adobe.com/reader. Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site: http://www.adobe.com/products/reader/tech-specs.html.
If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately – please let us have all your corrections within 48 hours. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.Offprints
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's Webshop. Corresponding authors who have published their article open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.
You can also check the status of your submitted article or find out when your accepted article will be published.
The Journal of Allergy and Clinical Immunology: In Practice
Editorial Office
Telephone: 319-356-7739
Fax: (319) 467-7583
Email: firstname.lastname@example.com


text:
Flash Player 10.3.181.16 for Windows Internet Explorer is now available.
This release addresses an issue with hardware acceleration on some systems with Intel HD Graphics adapters when viewing SWF content in Internet Explorer 9. With Flash Player 10.3.181.14 installed, SWF content appears in the upper-left corner of the screen. A full detailed description can be viewed by the Knowledge Base support article.


text:
L'Oréal Paris Infallible Never Fail Lipcolour Compact Reviews
it stay on.....but a bit dryingI don't know why the really low number either it's a good price point and the color really stays on. I do understand that perhaps the unhappiness stems from the fact that it does provoke a real dryness to the lips after a while! — 6 years, 9 months agodebra_covner_zak | 15 reviews
This product unfortunately didn't work for me.I purchased 2 of these at one time at CVS because they had a great deal. The color was beautiful, but the lipstick caked and was very dry. I ended up having flecks of the dry lipstick on my teeth. It sloughed off during the day. I like other products by L'Oreal, but this one didn't work. I had to throw the two lipsticks away. — 6 years, 10 months agoJessi74 | 11 reviews
Feels Like Silicone CaulkingI was so excited to try this product that I purchased two colors. I hate to admit that once I got it on and let it set for a couple of minutes then applied the sealer. Within two hours, I had lipstick marks on my teeth and my lips felt like I had applied a layer of silicon caulking. I had to stop using it because once that weird feeling came on, I was constantly running my teeth across my lips...read more like I was trying to remove dried skin. Results, more lipstick on my teeth and scrape marks in the lip spackling. I really think I am going to contact L'Oreal and see what they can do to remedy this problem because this Infallible failed miserably. — 6 years, 10 months agotyowinky13 | 8 reviews
DOES NOT WORKSorry, but I have purchased almost every color of L'Oreal Infallible lipstick there is, well my daughter gave me some, but it does not work for me, WHY?? I put it on, allow it to dry, then put the gloss over it, before I know it, it is ALL gone, except around the edges of my lips, which I cannot get off, it looks AWFUL!! It is SO expensive, how can you say it works?? I have used every color, a...read morend it all does the same, would be nice if it stayed on the entire lip, as it does around the mouth, but it does NOT!! First time I discovered it, I had not eaten or wiped my mouth, it had only been on a short time, went to the bathroom and gasped, I looked horrid!! Nothing but the outside of my lips were colored, it had all come off, can you tell me WHY???? Thanks!!! — 6 years, 11 months agoBindy | 1 reviews
5 starsI had to do a review on this because I also have it in the same shade but in the Loreal Stars secret signature lipstick. Of coarse I had to get this in Eva's Caramel, for those days that I like to have more of a long wearing lipstick. This product doesn't flake on me. I don't have any problems or concerns with it. I always keep in mind, if I don't want it too dark to make sure I apply it lightly a...read morend also apply the conditioning balm after to seal in the color. Make sure to apply the conditioning balm after 2 minutes or until absorbed on your lips. — 7 years agoLoyalty | 59 reviews
Yuck!I found a gorgeous shade of red, but honestly this was one of the worst lip products ever I've ever used. I tried it for a few days to give it a fair shot. The color never went on evenly, it dried out horribly around the edges, & talk about flake! It flaked on my teeth, all over anything i drank, & my lips were so dry & peeling after using this. This one just was not for me. — 7 years, 1 month agoiowagirl301 | 27 reviews
Good Timing = Long LastingI decided to try out this sensation because of allure. The first try, I didn't like it. Although the second time I figured out that I have to apply it quickly and then apply the gloss at just the right time as well and then it was an awesome result! The color lasted the full day, I forgot I was still wearing it and woke up in the morning and was amazed the color was still there. — 7 years, 3 months agolightwaves1636 | 1 reviews
L'Oreal Infallible Lipcolor in Plumped TawnyIn the past, I haven't had great experiences with L'Oreal's lipcolors. They were either too drying or no color payoff. Unfortunately, L'Oreal Infallible Lipcolor fails. While I do admit that Plumped Tawny is a pretty nude pink color, but it doesn't make up for its downfalls. Did I get plumped lips? Nope. Did it last six hours? Nope. During a meal and an evening out, L'Oreal Infallible Lipcolor did not last. — 7 years, 5 months agofabulessbeauty | 66 reviews
I am so happy to have found a long wearing lipstick that's comfortable!I absolutely love this product, I have two colors, Crimson and Mulberry. Crimson is a warm red, Mulberry is a neutral pink. I really like it for two reasons: the color doesn't dry out my lips like most long wearing lipsticks do, and the topcoat feels like a balm and isn't sticky or tacky. The color really lasts all day and stays comfortable, even before reapplying the top coat. It's the best long wearing lipstick that I've found! — 7 years, 6 months agorlmccue | 4 reviews
Love this stuff!I use this exclusively as my lipcolor. It lasts through almost anything, has great color choices and love the case with both together! The Lipfinity and Cover Girl Outlast has very similar properties and are good, but i like this one the best because of the case! Its singular, compact, fits well in my purse and is easy to use. I have tried most all the 'all day' lip colors, this is my recommended brand! (Walgreens often has it buy one get one free, Kroger often has it on sale as well). — 7 years, 8 months agosgrander | 6 reviews
to top
My Reasons for Reporting This


text:
Have a Tax Question? Ask a Tax Expert
Hello and thank you for contacting JustAnswer. We appreciate the opportunity to be of service to you,
While your argument may have merit, the only way to be sure is to attempt to take the "surrender charge" as a deduction and wait to be audited. There is no definite way to be sure. The question would be... where to you take the deduction?
The instructions for line 30 are very specific in that you are to enter any penalty from early withdrawal of savings or certificates of deposit from form 1099-INT. Absent that form there is no mechanism I know of to account for the deduction you are speaking about.
If you attempt to use Schedule A Investment Expense deduction you will find that expenses for passive losses are not allowed. Annuities would be considered passive investments.
It's not that I don't empathize with your position, it's just that I'm trying to play "devil's advocate".
If you have further questions about this topic please get back to me.
Let me know what you decide and how you make out.
How would you get it to the E. If you look at page 2 of the Schedule E those entries come from either K-1's, Partnerships, Passive Activities (business or real estate), etc.
I know of no tax letters, rulings, etc. that address this issue.
I just think it would be disallowed at audit.
If want further discussion on this issue I am happy to continue. If you decide to go ahead, let me know how you make out.